OS THERAPIES INCORPORATED Shareholders' Equity
OS THERAPIES INCORPORATED (OSTX) had Shareholders' Equity of -$11.91 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent -$11.91M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$10.82M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$6.10M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $3.64M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$11.91M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$10.82M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | -$6.10M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $3.64M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $4.94M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$4.19M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | -$3.27M 10-Q · filed 2026-08-14 | -$5.24M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$707.13K 10-Q · filed 2025-11-14 | -$707.13K 10-Q · filed 2024-11-15 |
| 2024-06-30 | -$27.06M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | -$25.51M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | -$24.02M 10-K · filed 2026-03-31 | |
| 2023-09-30 | -$22.52M 10-Q · filed 2024-11-15 | |
| 2023-06-30 | -$21.27M 10-Q · filed 2024-11-15 | |
| 2023-03-31 | -$18.74M 10-Q · filed 2024-11-15 | |
| 2022-12-31 | -$17.56M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |